NASUS PHARMA LTD NSRX
ASignal's systematic analysis rates NSRX as Bearish.
Reflects the latest available analysis · analyzed Nov 4, 2026
The case on NSRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $11.82M in total cash
- Low debt-to-equity ratio of 0.01x indicating minimal leverage
- High liquidity with current ratio of 8.77x and quick ratio of 8.42x
- Price trading near lower Bollinger Band, suggesting potential mean reversion
- Negative return on equity (-316.04%) and return on assets (-96.73%)
- Negative operating and gross margins indicating no profitability
- Negative free cash flow of -$6.98M and operating cash flow of -$10.52M
- MACD below signal line with negative histogram, indicating weak momentum
- Lack of revenue and earnings growth data suggests limited visibility
- Low news coverage with only two sources and no Reddit mentions
See the full verdict on NSRX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NSRX
Most investors never get a second opinion, let alone several. ASignal runs NSRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.